Oslo, Norway, August 6, 2026 – Nykode Therapeutics ASA (OSE: NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies, today announced that 1,000,000 share options have been granted to Jakob Helding Rasmussen in connection with his appointment as Chief Technology Officer of Nykode. The share options will have a strike price of NOK 7.00 per share, vest equally over a four-year vesting period and expire in 2031.
Please see further details in attached document.